Comparative Pharmacology
Head-to-head clinical analysis: FLUORESCEIN SODIUM versus FLUORESCITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORESCEIN SODIUM versus FLUORESCITE.
FLUORESCEIN SODIUM vs FLUORESCITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium is a diagnostic dye that absorbs light in the blue range (465-490 nm) and emits yellow-green fluorescence (520-530 nm) when exposed to excitation light. In angiography, it highlights retinal and choroidal vasculature, allowing visualization of blood flow, leakage, or defects in the blood-retinal barrier. It does not have intrinsic therapeutic pharmacological activity.
Fluorescein is a fluorescent dye that, after intravenous injection, distributes to the retinal and choroidal vasculature. It absorbs blue light at 490 nm and emits yellow-green fluorescence at 530 nm, allowing visualization of blood flow and leakage through the blood-retinal barrier.
5-10 mL of 10% solution (500-1000 mg) intravenously for angiography; 2 drops of 2% ophthalmic solution for diagnostic purposes.
5 mL (500 mg) intravenously, followed by a second dose after 30 minutes if needed. For children, 0.1 mL/kg (10 mg/kg) intravenously.
None Documented
None Documented
Terminal half-life ~24-36 hours; prolonged in renal impairment.
Terminal elimination half-life approximately 4–5 hours in adults with normal renal function; prolonged in renal impairment.
Primarily renal (80-90% unchanged); minor biliary/fecal (<10%).
Eliminated primarily via renal excretion as unchanged drug (90% within 72 hours); minor biliary/fecal elimination (<5%).
Category C
Category C
Ophthalmic Diagnostic Dye
Ophthalmic Diagnostic Dye